Dr Dave Pearson

In August 2021, Sygnature Discovery welcomed Dave Pearson as its Director of Form and Formulation, a position that perfectly aligns with his extensive expertise in solid form and formulation science, which spans over two decades. As a seasoned subject matter expert in solid form, Dave possesses a wealth of knowledge at the convergence of medicinal chemistry, process chemistry, DMPK, and pharmacology.

Under Dave’s direction, the Form and Formulation department facilitates the seamless transition of clients’ molecules from the laboratory to clinical applications. They achieve this by comprehensively understanding, controlling, and enhancing their solid-state properties, including crucial factors like crystallinity, stability, and dissolution profiles. This meticulous approach ensures that the developed processes are efficiently transferred to cGMP production, thereby streamlining the pathway to market readiness.

Dave’s expertise also includes formulating these molecules in the face of various challenges. Whether it involves addressing nonlinear PK profiles, circumventing first-pass metabolism, developing safer formulations, or designing fast and cost-effective first-in-human (FIH) studies, Dave’s insights expedite the make and test cycle beyond traditional GMP CDMOs.

Throughout his career, Dave has made substantial contributions to numerous early discovery and later stage development programs. His involvement has resulted in the successful delivery of over ten molecules to the market, while also leading teams that have achieved double this figure. This track record highlights his ability to enhance performance and minimize risk in delivering molecules to the clinic.

Dave holds a Ph.D. from the University of Sheffield and postdoctoral research experience from Imperial College London.